The Fiji Pharmaceuticals Biomedical Services (FPBS) is currently experiencing a shortage of medicine, which is linked to global supply chain disruptions rather than financial issues. Dr. Jemesa Tudravu, the Permanent Secretary for Health, explained that Fiji relies heavily on imported pharmaceuticals, as the country does not produce its own medicines.
Despite the government increasing its budget for medical products, delays in receiving supplies are primarily due to complications in transportation and documentation, as well as unexpected disruptions like strikes at ports worldwide. These factors significantly prolong the delivery process. According to Dr. Tudravu, issues as minor as a strike at a port in another country can lead to significant delays in medication delivery.
To tackle these challenges, Dr. Tudravu emphasized the importance of maintaining ongoing communication between FPBS and suppliers, even coordinating across different time zones to minimize delays. He also mentioned that while private hospitals are involved for medical testing when necessary, this typically occurs only when supplies are unavailable, thus affecting associated costs.
He expressed gratitude for the government’s continued commitment, highlighting another increase in the budget for medical supplies this year. The government is actively collaborating with suppliers to seek alternative sourcing options as part of their ongoing efforts to tackle the shortage.
Overall, the FPBS operations remain robust, with the health team working diligently to navigate the complex supply chain dynamics. This proactive approach ensures that the community’s healthcare needs are met, and that timely actions are taken to stabilize the situation.
In summary, while Fiji is facing challenges with medicine supply, the government’s dedication to increasing funding and exploring alternative solutions offers hope for a future resolution to these issues.
Leave a comment